#United States #Nashville #Cumberland Pharmaceuticals #Premier Inc. #Vibativ

Cumberland Pharmaceuticals Expands Vibativ® Access Through Premier, Inc.

In a notable development in the healthcare sector, Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical firm, has recently enhanced accessibility to its strong antibiotic, Vibativ® (telavancin), by adding it to a national group purchasing agreement with Premier, Inc. Effective from October 1, 2025, this agreement is set to benefit Premier's extensive membership base, which includes approximately 4,350 U.S. hospitals and more than 325,000 additional healthcare providers. This strategic move aims to streamline the ordering process for healthcare providers, giving them the flexibility to choose between the traditional 12-vial carton and the newly introduced 4-vial Starter Pak.

Enhanced Flexibility for Healthcare Providers

The addition of Vibativ® to Premier’s offerings supports both inpatient and outpatient settings, addressing varying patient needs effectively. The 12-vial carton continues to serve institutions handling a higher volume of patients, while the 4-vial Starter Pak caters to clinicians looking for a cost-efficient solution to manage patient therapies and inventory.

A.J. Kazimi, CEO of Cumberland Pharmaceuticals, expressed satisfaction with this new agreement, underscoring its potential to improve patient outcomes. He stated, “We’re pleased to expand the availability of Vibativ through Premier’s extensive network, giving thousands of hospitals and providers access to the product’s standard carton and the new Starter Pak.”

This collaboration with Premier is a crucial step towards fulfilling Cumberland's mission to offer flexible and economically viable solutions for treating difficult Gram-positive infections.

Vibativ®: A Powerful Antibiotic Solution

Vibativ® is a once-daily injectable lipoglycopeptide antibiotic that has been specifically designed to combat drug-resistant bacteria, including strains of Staphylococcus aureus (S. aureus). It is indicated for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin and skin structure infections (cSSSI).

What sets Vibativ® apart is its dual mechanism of action, which enables it to penetrate deeply into bacterial cell walls and effectively inhibit their growth, a significant advantage in an era where antibiotic resistance is on the rise. With a proven track record, Vibativ® has maintained its efficacy against difficult-to-treat and multidrug-resistant infections for over ten years.

Recent reports from the World Health Organization (WHO) highlight a growing global health crisis marked by antimicrobial resistance (AMR). The rise in antibiotic-resistant pathogens underscores the need for effective treatments like Vibativ®, which were intentionally designed to tackle such resistant strains by modifying the existing antibiotic vancomycin.

By introducing fat-loving and water-loving components, Vibativ® boasts enhanced cell wall penetration abilities, allowing it to reach and eradicate infections that are typically untreatable.

Proven Efficacy and Study Results

Clinical studies have demonstrated that Vibativ® is not only effective but also shows comparable, if not superior, cure rates against Gram-positive pathogens when compared to traditional antibiotics such as vancomycin, particularly in cases where infections are complicated by bacteremia.

The strong data supporting Vibativ's efficacy has laid a solid foundation for its implementation in treatment regimens for patients suffering from serious gram-positive infections, as evidenced by extensive multinational studies involving diverse patient populations.

A Commitment to Patient Care

Cumberland Pharmaceuticals, headquartered in Tennessee, has continuously dedicated itself to improving patient care through innovative therapeutic solutions. In addition to Vibativ®, the company offers a portfolio of FDA-approved medications targeting various medical needs, including pain management and gastroenterological conditions. Their commitment to combatting complex bacterial infections resonates strongly within the broader industry context.

In line with their mission, Cumberland Pharmaceuticals invites healthcare professionals seeking information about Vibativ® to visit their website at www.vibativ.com/order. For any medical inquiries, they are encouraged to reach out to the company's Medical Affairs division.

As Cumberland Pharmaceuticals expands its presence in the healthcare landscape, the collaboration with Premier Inc. marks an essential milestone in their ongoing mission to ensure patients receive quality care through effective treatments.

For further details on Vibativ® and other products from Cumberland Pharmaceuticals, please consult their comprehensive resource available on their official website. By prioritizing innovative treatment strategies, they continue to navigate the challenges posed by antibiotic resistance, aiming for improved patient outcomes in acute care settings.